Integrated Research Reports 13-17% Pro Forma Revenue Decline and 27% Cash Increase in FY26
Integrated Research (ASX:IRI) reported a 13-17% decline in pro forma revenue for FY26, weighed down by a softer renewals book and weaker new business in H2. Despite this, cash reserves rose 27%, underpinning ongoing investment in the company’s product-led growth strategy.
- Pro forma revenue down 13-17% due to renewals softness and deferred new deals
- EBITDA improved modestly in H2 but full year hit by credit losses and FX
- Cash increased 27% to A$51.7 million, enabling continued innovation funding
- Product-led growth remains core strategy amid challenges sustaining new business
- AI-driven cautious tech spending highlighted as FY27 priority by CEO Ian Lowe
Revenue Growth Stalls as Renewals Weaken
Integrated Research’s FY26 trading update reveals a challenging year marked by a 13-17% decline in pro forma revenue to an estimated A$56-58 million, down from A$68.3 million in FY25. The softness in renewals, which fluctuate annually, combined with a slowdown in new business during the second half, weighed heavily on top-line performance. Several new contracts expected to close in H2 were deferred into the first half of FY27, exacerbating revenue churn.
EBITDA and Earnings Impacted by Credit and Currency
While EBITDA showed modest improvement in the second half, the full-year result was dragged down by increased expected credit losses and foreign exchange headwinds. The company described the year-on-year statutory earnings comparison as not meaningful, reflecting these non-operational impacts. Nonetheless, the underlying operating performance highlights ongoing pressure on profitability amid investment in growth initiatives.
Strong Cash Position Fuels Product-Led Growth
Cash reserves climbed 27% to A$51.7 million, providing a robust foundation for Integrated Research to continue funding its product-led growth strategy. This approach focuses on driving sustainable new business revenue through innovation and client engagement, pivoting away from reliance on fluctuating renewals. CEO Ian Lowe emphasised that despite the challenging financial backdrop, the company advanced its product delivery and innovation capabilities throughout FY26.
AI and Cautious Tech Spending Shape FY27 Priorities
Lowe highlighted the increasing caution among technology buyers driven by AI developments, underscoring the importance of accelerating monetisation of new products and expanding client-led innovation. Integrated Research’s trusted position with global organisations is seen as a platform to regain momentum. The company’s strategy to convert term licence fees to a recurring subscription model remains central to managing revenue predictability and growth.
Looking Ahead to FY27
With multiple new business deals deferred into FY27, the upcoming year will test Integrated Research’s ability to translate product innovation into sustainable revenue growth. The company’s strong cash position supports ongoing investment, but the challenge remains to outpace revenue churn with new sales in a cautious tech spending environment. Market participants will be watching closely how the product-led growth strategy and AI-driven offerings perform in the months ahead.
Bottom Line?
Integrated Research’s FY26 results underscore the difficulty of balancing innovation investment with revenue stability, leaving FY27’s new business pipeline and product monetisation execution as critical factors for recovery.
Questions in the middle?
- Can Integrated Research accelerate new business wins to exceed revenue churn in FY27?
- How will AI-driven cautious spending impact demand for IR’s observability solutions?
- Will the shift to subscription revenue models improve long-term financial predictability?
